Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Joachim F. Wernicke"'
Autor:
Joachim F. Wernicke, Smriti Iyengar, Shuyu Zhang, Karla Alaka, Vladimir Skljarevski, Deborah N. D'Souza, Amy S. Chappell
Publikováno v:
Current Drug Therapy
The primary objective of this study is to review the efficacy of duloxetine in treating chronic pain using the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommendations for clinical significance across chron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3aa85d5068266f7cca6e55239b32304
https://doi.org/10.2174/157488511798109592
https://doi.org/10.2174/157488511798109592
Publikováno v:
Frontiers in Bioscience. :106-111
The placebo effect has been extensively studied in many disease states, some of the most notable being pain and depression. Utilizing a Medline search, studies were identified that reported on areas of the brain shown to be involved in either placebo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f652bb80d6eaa1c4293c3b9eb162aa32
https://doi.org/10.2741/s49
https://doi.org/10.2741/s49
Autor:
Joachim F. Wernicke, J. Hall, Adam L. Meyers, Sara E. Edwards, Joel Raskin, Michael J. Robinson, Sarah Lipsius, Bill H. McCarberg, Ajay D. Wasan, Melissa J. Ossanna
Publikováno v:
Current Drug Safety. 4:22-29
Objective: We present a post-hoc analysis of the safety and efficacy of duloxetine, a selective serotonin/ norepinephrine reuptake inhibitor, for treatment of diabetic peripheral neuropathic pain (DPNP) in older patients. Methods: Data from three dou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f29cc6f8fdfa32ae97e4a35cbda31efd
https://doi.org/10.2174/157488609787354404
https://doi.org/10.2174/157488609787354404
Publikováno v:
Current Medical Research and Opinion. 24:3105-3115
Debate continues regarding whether onset of analgesia is faster than antidepressant effect in antidepressants with both properties. Duloxetine hydrochloride (from here on referred to as duloxetine) is effective in both major depressive disorder and d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::907c6034e149b8bd70b3dbfbd20e4ef0
https://doi.org/10.1185/03007990802429627
https://doi.org/10.1185/03007990802429627
Autor:
Isabelle Murray, Joachim F. Wernicke, Mary Pat Knadler, Deborah N. D'Souza, Judith W. Henck, Fujun Wang, Beth A. Pangallo, Jack Uetrecht
Publikováno v:
Current Drug Safety. 3:132-142
Objective: Review nonclinical and clinical trial data for hepatic effects of duloxetine. Methods: Review studies of toxicology, metabolism, mitochondrial effects, and clinical trials. Results: Nonclinical studies revealed no treatment-related transam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd5d64050a91507a5df4cfc84e5545d5
https://doi.org/10.2174/157488608784529189
https://doi.org/10.2174/157488608784529189
Autor:
Madelaine M. Wohlreich, Nayan Acharya, Indiana Strombom, Louis Kuritzky, Michael Robinson, Alexandra N. Heinloth, Arie Regev, Joachim F. Wernicke
Publikováno v:
Postgraduate Medicine. 120:111-118
Since its first FDA approval in 2004, duloxetine has been taken by more than 5 million patients. A small fraction of patients treated with duloxetine develop elevations in liver enzymes, which generally resolve spontaneously without any change in tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da0718e4102fea8f911a66626db64e17
https://doi.org/10.3810/pgm.2008.07.1803
https://doi.org/10.3810/pgm.2008.07.1803
Autor:
Joachim F. Wernicke, Holly A. Read, Arie Regev, Albert J. Allen, Durisala Desaiah, Mark E. Bangs, Shuyu Zhang, Ling Jin
Publikováno v:
Drug Safety. 31:345-354
This study describes and assesses potential hepatobiliary events related to atomoxetine therapy, as reported in clinical trials and as spontaneous adverse event reports post-launch in 2002.Case reports that contained potential hepatobiliary events we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::475be75095c87bcfc0bcf6beb1116fed
https://doi.org/10.2165/00002018-200831040-00008
https://doi.org/10.2165/00002018-200831040-00008
Autor:
Lesley M. Arnold, Daniel K. Kajdasz, Joachim F. Wernicke, Yili Pritchett, Smriti Iyengar, Deborah N. D'Souza
Publikováno v:
Journal of Women's Health. 16:1145-1156
To assess the efficacy (in particular, in pain, functional impairment, and quality of life) and safety and tolerability (incidence of adverse events, discontinuation rates, changes in laboratory findings, and vital signs) of duloxetine in female pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29d833d989d54ad4f247ddff6d4a792e
https://doi.org/10.1089/jwh.2006.0213
https://doi.org/10.1089/jwh.2006.0213
Publikováno v:
Current Drug Therapy. 2:161-167
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70719f7beca0bc4d882e9f3c5c78323c
https://doi.org/10.2174/157488507780619086
https://doi.org/10.2174/157488507780619086
Publikováno v:
Drug Safety. 30:437-455
Background and objective: In recent years, new classes of medication, such as the serotonin-noradrenaline reuptake inhibitors (SNRIs), have been developed for use in the treatment of major depressive disorder (MDD). For many years, treatment options
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ec1072671fdd1b9f5c690a388bd5399
https://doi.org/10.2165/00002018-200730050-00007
https://doi.org/10.2165/00002018-200730050-00007